Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Revolution Medicines down 15% in after-hours after AbbVie denies takeover talks
- AbbVie tells Bloomberg not in talks to buy Revolution Medicines
- AbbVie says not in discussions with Revolution Medicines, Reuters reports
- Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines
- Revolution Medicines extends gain to 29% after resuming trading